Q1 2024 Round Up
Situation Normal?
The Evaluate team are back from the 2023 ASCO Annual Meeting reporting on all the big data drops and breakthroughs in cancer care.
Foreword
Q1 2024 Posts Big M&A Total Led By Novo Holdings’ Catalent Takeout
Venture Capital Fundraising Rebounds In Q1 As Mega-Rounds Dominate
Normality Reasserts Itself For Biotech IPOs
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
HOW WE HELP